nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—P-Glycoprotein Inhibitors—Cyclosporine—psoriasis	0.476	1	CiPCiCtD
Crizotinib—TYK2—psoriasis	0.26	1	CbGaD
Crizotinib—CYP3A5—Beclomethasone—psoriasis	0.01	0.179	CbGbCtD
Crizotinib—ACVR1—pes—psoriasis	0.00451	0.117	CbGeAlD
Crizotinib—CYP3A5—Mycophenolate mofetil—psoriasis	0.00398	0.0714	CbGbCtD
Crizotinib—CYP3A4—Calcitriol—psoriasis	0.00347	0.0623	CbGbCtD
Crizotinib—CYP3A5—Hydrocortisone—psoriasis	0.00319	0.0573	CbGbCtD
Crizotinib—CYP3A5—Cyclosporine—psoriasis	0.00302	0.0541	CbGbCtD
Crizotinib—CYP3A4—Methoxsalen—psoriasis	0.0027	0.0485	CbGbCtD
Crizotinib—ABCB1—Mycophenolate mofetil—psoriasis	0.00259	0.0464	CbGbCtD
Crizotinib—ABCB1—Betamethasone—psoriasis	0.00222	0.0399	CbGbCtD
Crizotinib—ABCB1—Prednisolone—psoriasis	0.00219	0.0393	CbGbCtD
Crizotinib—BMP2K—synovial membrane of synovial joint—psoriasis	0.00215	0.0558	CbGeAlD
Crizotinib—ABCB1—Hydrocortisone—psoriasis	0.00208	0.0373	CbGbCtD
Crizotinib—ABCB1—Prednisone—psoriasis	0.00207	0.0371	CbGbCtD
Crizotinib—RIPK2—synovial membrane of synovial joint—psoriasis	0.00206	0.0534	CbGeAlD
Crizotinib—CYP3A5—Dexamethasone—psoriasis	0.00199	0.0356	CbGbCtD
Crizotinib—ABCB1—Cyclosporine—psoriasis	0.00196	0.0352	CbGbCtD
Crizotinib—CYP3A4—Cholecalciferol—psoriasis	0.00179	0.0321	CbGbCtD
Crizotinib—IGF1R—skin epidermis—psoriasis	0.00165	0.0429	CbGeAlD
Crizotinib—CYP3A4—Mycophenolate mofetil—psoriasis	0.00155	0.0278	CbGbCtD
Crizotinib—CYP3A4—Triamcinolone—psoriasis	0.00155	0.0278	CbGbCtD
Crizotinib—CYP3A4—Betamethasone—psoriasis	0.00133	0.0239	CbGbCtD
Crizotinib—ROS1—tendon—psoriasis	0.00132	0.0342	CbGeAlD
Crizotinib—CYP3A4—Prednisolone—psoriasis	0.00131	0.0236	CbGbCtD
Crizotinib—ABCB1—Dexamethasone—psoriasis	0.00129	0.0232	CbGbCtD
Crizotinib—CYP3A4—Hydrocortisone—psoriasis	0.00125	0.0223	CbGbCtD
Crizotinib—CYP3A4—Prednisone—psoriasis	0.00124	0.0222	CbGbCtD
Crizotinib—PTK2—skin epidermis—psoriasis	0.00123	0.0318	CbGeAlD
Crizotinib—CYP3A4—Cyclosporine—psoriasis	0.00118	0.0211	CbGbCtD
Crizotinib—TIE1—endothelium—psoriasis	0.00117	0.0303	CbGeAlD
Crizotinib—MUSK—tendon—psoriasis	0.00112	0.0291	CbGeAlD
Crizotinib—ABCB1—Methotrexate—psoriasis	0.00104	0.0186	CbGbCtD
Crizotinib—RIPK2—endothelium—psoriasis	0.00096	0.0249	CbGeAlD
Crizotinib—PTK2—endothelium—psoriasis	0.000891	0.0231	CbGeAlD
Crizotinib—EPHB4—endothelium—psoriasis	0.000811	0.021	CbGeAlD
Crizotinib—TEK—endothelium—psoriasis	0.000776	0.0201	CbGeAlD
Crizotinib—CYP3A4—Dexamethasone—psoriasis	0.000774	0.0139	CbGbCtD
Crizotinib—SRC—endothelium—psoriasis	0.000689	0.0179	CbGeAlD
Crizotinib—MET—skin of body—psoriasis	0.000652	0.0169	CbGeAlD
Crizotinib—LIMK1—tendon—psoriasis	0.000589	0.0153	CbGeAlD
Crizotinib—TYRO3—skin of body—psoriasis	0.000533	0.0138	CbGeAlD
Crizotinib—MAPK7—tendon—psoriasis	0.00053	0.0137	CbGeAlD
Crizotinib—FES—tendon—psoriasis	0.000525	0.0136	CbGeAlD
Crizotinib—IGF1R—skin of body—psoriasis	0.000513	0.0133	CbGeAlD
Crizotinib—MET—tendon—psoriasis	0.000496	0.0129	CbGeAlD
Crizotinib—TAOK2—tendon—psoriasis	0.000476	0.0123	CbGeAlD
Crizotinib—STK35—skin of body—psoriasis	0.000444	0.0115	CbGeAlD
Crizotinib—DCLK1—tendon—psoriasis	0.000435	0.0113	CbGeAlD
Crizotinib—RIPK2—skin of body—psoriasis	0.00041	0.0106	CbGeAlD
Crizotinib—CASK—Mycophenolic acid—Mycophenolate mofetil—psoriasis	0.000409	0.161	CbGdCrCtD
Crizotinib—FER—tendon—psoriasis	0.000406	0.0105	CbGeAlD
Crizotinib—TNK1—tendon—psoriasis	0.000402	0.0104	CbGeAlD
Crizotinib—MAP4K1—tendon—psoriasis	0.000398	0.0103	CbGeAlD
Crizotinib—MAP4K2—tendon—psoriasis	0.000385	0.00997	CbGeAlD
Crizotinib—PTK2—skin of body—psoriasis	0.00038	0.00986	CbGeAlD
Crizotinib—STK3—tendon—psoriasis	0.00038	0.00984	CbGeAlD
Crizotinib—TYK2—skin of body—psoriasis	0.000378	0.00979	CbGeAlD
Crizotinib—AURKA—tendon—psoriasis	0.00037	0.00959	CbGeAlD
Crizotinib—TESK1—tendon—psoriasis	0.000367	0.00951	CbGeAlD
Crizotinib—AXL—skin of body—psoriasis	0.000362	0.00939	CbGeAlD
Crizotinib—MERTK—tendon—psoriasis	0.000357	0.00925	CbGeAlD
Crizotinib—MAP3K12—tendon—psoriasis	0.000345	0.00895	CbGeAlD
Crizotinib—ACVR1—tendon—psoriasis	0.000345	0.00895	CbGeAlD
Crizotinib—JAK2—skin of body—psoriasis	0.000344	0.00891	CbGeAlD
Crizotinib—STK35—tendon—psoriasis	0.000338	0.00877	CbGeAlD
Crizotinib—MAP3K3—skin of body—psoriasis	0.000331	0.00859	CbGeAlD
Crizotinib—ABL2—tendon—psoriasis	0.00033	0.00854	CbGeAlD
Crizotinib—BMP2K—tendon—psoriasis	0.000326	0.00844	CbGeAlD
Crizotinib—EPHB6—skin of body—psoriasis	0.000317	0.00821	CbGeAlD
Crizotinib—PTK2B—tendon—psoriasis	0.000314	0.00815	CbGeAlD
Crizotinib—RIPK2—tendon—psoriasis	0.000312	0.00808	CbGeAlD
Crizotinib—CDK7—Mycophenolic acid—Mycophenolate mofetil—psoriasis	0.00031	0.122	CbGdCrCtD
Crizotinib—EPHA4—tendon—psoriasis	0.000301	0.00781	CbGeAlD
Crizotinib—SRC—skin of body—psoriasis	0.000294	0.00763	CbGeAlD
Crizotinib—PTK2—tendon—psoriasis	0.00029	0.00751	CbGeAlD
Crizotinib—TBK1—tendon—psoriasis	0.00029	0.00751	CbGeAlD
Crizotinib—TYK2—tendon—psoriasis	0.000288	0.00746	CbGeAlD
Crizotinib—IRAK1—tendon—psoriasis	0.000284	0.00736	CbGeAlD
Crizotinib—AURKA—Mycophenolate mofetil—Mycophenolic acid—psoriasis	0.00028	0.11	CbGdCrCtD
Crizotinib—RPS6KB1—tendon—psoriasis	0.000279	0.00722	CbGeAlD
Crizotinib—FGR—tendon—psoriasis	0.000277	0.00718	CbGeAlD
Crizotinib—AXL—tendon—psoriasis	0.000276	0.00715	CbGeAlD
Crizotinib—SLK—tendon—psoriasis	0.000265	0.00688	CbGeAlD
Crizotinib—CSF1R—skin of body—psoriasis	0.000264	0.00685	CbGeAlD
Crizotinib—EPHB4—tendon—psoriasis	0.000264	0.00683	CbGeAlD
Crizotinib—JAK2—tendon—psoriasis	0.000262	0.00678	CbGeAlD
Crizotinib—EPHA2—tendon—psoriasis	0.000259	0.0067	CbGeAlD
Crizotinib—MAP3K3—tendon—psoriasis	0.000252	0.00654	CbGeAlD
Crizotinib—TEK—tendon—psoriasis	0.000252	0.00654	CbGeAlD
Crizotinib—MAP4K5—tendon—psoriasis	0.000252	0.00654	CbGeAlD
Crizotinib—EPHB6—tendon—psoriasis	0.000241	0.00625	CbGeAlD
Crizotinib—YES1—tendon—psoriasis	0.000233	0.00604	CbGeAlD
Crizotinib—STK10—tendon—psoriasis	0.000231	0.00598	CbGeAlD
Crizotinib—TAOK3—tendon—psoriasis	0.00023	0.00596	CbGeAlD
Crizotinib—ABL1—skin of body—psoriasis	0.000209	0.00541	CbGeAlD
Crizotinib—CSF1R—tendon—psoriasis	0.000201	0.00521	CbGeAlD
Crizotinib—ABL1—tendon—psoriasis	0.000159	0.00412	CbGeAlD
Crizotinib—AURKA—Mycophenolic acid—Mycophenolate mofetil—psoriasis	0.000158	0.0623	CbGdCrCtD
Crizotinib—AURKA—Calcipotriol—Calcitriol—psoriasis	9.29e-05	0.0366	CbGdCrCtD
Crizotinib—Bradycardia—Triamcinolone—psoriasis	7.9e-05	0.00108	CcSEcCtD
Crizotinib—AURKA—Calcipotriol—Cholecalciferol—psoriasis	7.9e-05	0.0311	CbGdCrCtD
Crizotinib—Malnutrition—Mycophenolate mofetil—psoriasis	7.88e-05	0.00108	CcSEcCtD
Crizotinib—Vomiting—Acitretin—psoriasis	7.88e-05	0.00108	CcSEcCtD
Crizotinib—Vomiting—Fluocinolone Acetonide—psoriasis	7.86e-05	0.00108	CcSEcCtD
Crizotinib—Muscular weakness—Prednisone—psoriasis	7.82e-05	0.00107	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Prednisone—psoriasis	7.82e-05	0.00107	CcSEcCtD
Crizotinib—Visual disturbance—Methotrexate—psoriasis	7.82e-05	0.00107	CcSEcCtD
Crizotinib—Rash—Acitretin—psoriasis	7.81e-05	0.00107	CcSEcCtD
Crizotinib—Dermatitis—Acitretin—psoriasis	7.8e-05	0.00107	CcSEcCtD
Crizotinib—Rash—Fluocinolone Acetonide—psoriasis	7.79e-05	0.00107	CcSEcCtD
Crizotinib—Dermatitis—Fluocinolone Acetonide—psoriasis	7.78e-05	0.00107	CcSEcCtD
Crizotinib—Dysgeusia—Mycophenolate mofetil—psoriasis	7.71e-05	0.00106	CcSEcCtD
Crizotinib—Eye disorder—Hydrocortisone—psoriasis	7.7e-05	0.00106	CcSEcCtD
Crizotinib—Neuropathy peripheral—Betamethasone—psoriasis	7.69e-05	0.00105	CcSEcCtD
Crizotinib—Neuropathy peripheral—Dexamethasone—psoriasis	7.69e-05	0.00105	CcSEcCtD
Crizotinib—Body temperature increased—Hydroxyurea—psoriasis	7.69e-05	0.00105	CcSEcCtD
Crizotinib—Vision blurred—Cyclosporine—psoriasis	7.61e-05	0.00104	CcSEcCtD
Crizotinib—Arrhythmia—Prednisolone—psoriasis	7.54e-05	0.00103	CcSEcCtD
Crizotinib—Anaemia—Cyclosporine—psoriasis	7.46e-05	0.00102	CcSEcCtD
Crizotinib—Arrhythmia—Hydrocortisone—psoriasis	7.36e-05	0.00101	CcSEcCtD
Crizotinib—Nausea—Acitretin—psoriasis	7.36e-05	0.00101	CcSEcCtD
Crizotinib—Nausea—Fluocinolone Acetonide—psoriasis	7.34e-05	0.00101	CcSEcCtD
Crizotinib—Paraesthesia—Mycophenolic acid—psoriasis	7.32e-05	0.001	CcSEcCtD
Crizotinib—Anaemia—Mycophenolate mofetil—psoriasis	7.28e-05	0.000998	CcSEcCtD
Crizotinib—Dyspnoea—Mycophenolic acid—psoriasis	7.26e-05	0.000996	CcSEcCtD
Crizotinib—Leukopenia—Cyclosporine—psoriasis	7.23e-05	0.000991	CcSEcCtD
Crizotinib—Malnutrition—Hydrocortisone—psoriasis	7.18e-05	0.000984	CcSEcCtD
Crizotinib—Dyspepsia—Mycophenolic acid—psoriasis	7.17e-05	0.000983	CcSEcCtD
Crizotinib—Bradycardia—Betamethasone—psoriasis	7.17e-05	0.000983	CcSEcCtD
Crizotinib—Bradycardia—Dexamethasone—psoriasis	7.17e-05	0.000983	CcSEcCtD
Crizotinib—Neutropenia—Prednisone—psoriasis	7.17e-05	0.000982	CcSEcCtD
Crizotinib—ACVR1—Betamethasone—Clobetasol propionate—psoriasis	7.12e-05	0.0281	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Clobetasol propionate—psoriasis	7.12e-05	0.0281	CbGdCrCtD
Crizotinib—Decreased appetite—Mycophenolic acid—psoriasis	7.08e-05	0.000971	CcSEcCtD
Crizotinib—Syncope—Mycophenolate mofetil—psoriasis	7.06e-05	0.000968	CcSEcCtD
Crizotinib—Leukopenia—Mycophenolate mofetil—psoriasis	7.05e-05	0.000967	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Mycophenolic acid—psoriasis	7.03e-05	0.000964	CcSEcCtD
Crizotinib—Fatigue—Mycophenolic acid—psoriasis	7.02e-05	0.000963	CcSEcCtD
Crizotinib—Asthenia—Hydroxyurea—psoriasis	6.98e-05	0.000957	CcSEcCtD
Crizotinib—Constipation—Mycophenolic acid—psoriasis	6.97e-05	0.000955	CcSEcCtD
Crizotinib—Arrhythmia—Triamcinolone—psoriasis	6.93e-05	0.000951	CcSEcCtD
Crizotinib—Weight decreased—Prednisone—psoriasis	6.93e-05	0.00095	CcSEcCtD
Crizotinib—Vision blurred—Prednisolone—psoriasis	6.93e-05	0.000949	CcSEcCtD
Crizotinib—Loss of consciousness—Mycophenolate mofetil—psoriasis	6.92e-05	0.000949	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	6.83e-05	0.000936	CcSEcCtD
Crizotinib—Visual impairment—Betamethasone—psoriasis	6.79e-05	0.000931	CcSEcCtD
Crizotinib—Visual impairment—Dexamethasone—psoriasis	6.79e-05	0.000931	CcSEcCtD
Crizotinib—Neuropathy peripheral—Prednisone—psoriasis	6.7e-05	0.000918	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	6.66e-05	0.000913	CcSEcCtD
Crizotinib—Diarrhoea—Hydroxyurea—psoriasis	6.66e-05	0.000912	CcSEcCtD
Crizotinib—Dysgeusia—Triamcinolone—psoriasis	6.62e-05	0.000907	CcSEcCtD
Crizotinib—Oedema—Cyclosporine—psoriasis	6.59e-05	0.000903	CcSEcCtD
Crizotinib—Syncope—Prednisolone—psoriasis	6.59e-05	0.000903	CcSEcCtD
Crizotinib—Eye disorder—Betamethasone—psoriasis	6.58e-05	0.000902	CcSEcCtD
Crizotinib—Eye disorder—Dexamethasone—psoriasis	6.58e-05	0.000902	CcSEcCtD
Crizotinib—Infection—Cyclosporine—psoriasis	6.55e-05	0.000898	CcSEcCtD
Crizotinib—Nervous system disorder—Cyclosporine—psoriasis	6.46e-05	0.000886	CcSEcCtD
Crizotinib—Loss of consciousness—Prednisolone—psoriasis	6.46e-05	0.000885	CcSEcCtD
Crizotinib—Body temperature increased—Mycophenolic acid—psoriasis	6.44e-05	0.000883	CcSEcCtD
Crizotinib—Syncope—Hydrocortisone—psoriasis	6.44e-05	0.000882	CcSEcCtD
Crizotinib—Dizziness—Hydroxyurea—psoriasis	6.43e-05	0.000882	CcSEcCtD
Crizotinib—Oedema—Mycophenolate mofetil—psoriasis	6.43e-05	0.000881	CcSEcCtD
Crizotinib—Skin disorder—Cyclosporine—psoriasis	6.4e-05	0.000878	CcSEcCtD
Crizotinib—Infection—Mycophenolate mofetil—psoriasis	6.39e-05	0.000876	CcSEcCtD
Crizotinib—Shock—Mycophenolate mofetil—psoriasis	6.33e-05	0.000867	CcSEcCtD
Crizotinib—Loss of consciousness—Hydrocortisone—psoriasis	6.31e-05	0.000865	CcSEcCtD
Crizotinib—Nervous system disorder—Mycophenolate mofetil—psoriasis	6.3e-05	0.000864	CcSEcCtD
Crizotinib—Arrhythmia—Dexamethasone—psoriasis	6.29e-05	0.000863	CcSEcCtD
Crizotinib—Arrhythmia—Betamethasone—psoriasis	6.29e-05	0.000863	CcSEcCtD
Crizotinib—Skin disorder—Mycophenolate mofetil—psoriasis	6.24e-05	0.000856	CcSEcCtD
Crizotinib—Bradycardia—Prednisone—psoriasis	6.24e-05	0.000856	CcSEcCtD
Crizotinib—Vomiting—Hydroxyurea—psoriasis	6.18e-05	0.000848	CcSEcCtD
Crizotinib—Rash—Hydroxyurea—psoriasis	6.13e-05	0.000841	CcSEcCtD
Crizotinib—Dermatitis—Hydroxyurea—psoriasis	6.13e-05	0.00084	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	6.07e-05	0.000832	CcSEcCtD
Crizotinib—Syncope—Triamcinolone—psoriasis	6.06e-05	0.000831	CcSEcCtD
Crizotinib—Oedema—Prednisolone—psoriasis	6e-05	0.000822	CcSEcCtD
Crizotinib—Neutropenia—Methotrexate—psoriasis	5.99e-05	0.000821	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Methotrexate—psoriasis	5.95e-05	0.000816	CcSEcCtD
Crizotinib—Loss of consciousness—Triamcinolone—psoriasis	5.94e-05	0.000814	CcSEcCtD
Crizotinib—Paraesthesia—Cyclosporine—psoriasis	5.92e-05	0.000811	CcSEcCtD
Crizotinib—Shock—Prednisolone—psoriasis	5.9e-05	0.000809	CcSEcCtD
Crizotinib—Dyspnoea—Cyclosporine—psoriasis	5.88e-05	0.000805	CcSEcCtD
Crizotinib—Oedema—Hydrocortisone—psoriasis	5.86e-05	0.000803	CcSEcCtD
Crizotinib—Asthenia—Mycophenolic acid—psoriasis	5.85e-05	0.000801	CcSEcCtD
Crizotinib—Infection—Hydrocortisone—psoriasis	5.82e-05	0.000798	CcSEcCtD
Crizotinib—Dyspepsia—Cyclosporine—psoriasis	5.8e-05	0.000795	CcSEcCtD
Crizotinib—Nausea—Hydroxyurea—psoriasis	5.78e-05	0.000792	CcSEcCtD
Crizotinib—Paraesthesia—Mycophenolate mofetil—psoriasis	5.77e-05	0.000791	CcSEcCtD
Crizotinib—Shock—Hydrocortisone—psoriasis	5.76e-05	0.00079	CcSEcCtD
Crizotinib—Nervous system disorder—Hydrocortisone—psoriasis	5.74e-05	0.000787	CcSEcCtD
Crizotinib—Pneumonia—Methotrexate—psoriasis	5.74e-05	0.000787	CcSEcCtD
Crizotinib—Eye disorder—Prednisone—psoriasis	5.73e-05	0.000786	CcSEcCtD
Crizotinib—Dyspnoea—Mycophenolate mofetil—psoriasis	5.73e-05	0.000786	CcSEcCtD
Crizotinib—Decreased appetite—Cyclosporine—psoriasis	5.73e-05	0.000785	CcSEcCtD
Crizotinib—Infestation—Methotrexate—psoriasis	5.71e-05	0.000783	CcSEcCtD
Crizotinib—Infestation NOS—Methotrexate—psoriasis	5.71e-05	0.000783	CcSEcCtD
Crizotinib—ACVR1—Dexamethasone—Fluocinonide—psoriasis	5.71e-05	0.0225	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Beclomethasone—psoriasis	5.71e-05	0.0225	CbGdCrCtD
Crizotinib—ACVR1—Betamethasone—Beclomethasone—psoriasis	5.71e-05	0.0225	CbGdCrCtD
Crizotinib—ACVR1—Betamethasone—Fluocinonide—psoriasis	5.71e-05	0.0225	CbGdCrCtD
Crizotinib—Gastrointestinal disorder—Cyclosporine—psoriasis	5.69e-05	0.00078	CcSEcCtD
Crizotinib—Skin disorder—Hydrocortisone—psoriasis	5.69e-05	0.00078	CcSEcCtD
Crizotinib—Fatigue—Cyclosporine—psoriasis	5.68e-05	0.000779	CcSEcCtD
Crizotinib—Dyspepsia—Mycophenolate mofetil—psoriasis	5.66e-05	0.000776	CcSEcCtD
Crizotinib—Constipation—Cyclosporine—psoriasis	5.64e-05	0.000773	CcSEcCtD
Crizotinib—Decreased appetite—Mycophenolate mofetil—psoriasis	5.59e-05	0.000766	CcSEcCtD
Crizotinib—Diarrhoea—Mycophenolic acid—psoriasis	5.57e-05	0.000764	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	5.55e-05	0.000761	CcSEcCtD
Crizotinib—ACVR1—Betamethasone—Fluocinolone Acetonide—psoriasis	5.54e-05	0.0218	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Fluocinolone Acetonide—psoriasis	5.54e-05	0.0218	CbGdCrCtD
Crizotinib—Oedema—Triamcinolone—psoriasis	5.52e-05	0.000756	CcSEcCtD
Crizotinib—Syncope—Betamethasone—psoriasis	5.5e-05	0.000754	CcSEcCtD
Crizotinib—Syncope—Dexamethasone—psoriasis	5.5e-05	0.000754	CcSEcCtD
Crizotinib—Constipation—Mycophenolate mofetil—psoriasis	5.5e-05	0.000754	CcSEcCtD
Crizotinib—Arrhythmia—Prednisone—psoriasis	5.48e-05	0.000751	CcSEcCtD
Crizotinib—Infection—Triamcinolone—psoriasis	5.48e-05	0.000751	CcSEcCtD
Crizotinib—Shock—Triamcinolone—psoriasis	5.43e-05	0.000744	CcSEcCtD
Crizotinib—Hepatobiliary disease—Methotrexate—psoriasis	5.4e-05	0.00074	CcSEcCtD
Crizotinib—Loss of consciousness—Betamethasone—psoriasis	5.39e-05	0.000739	CcSEcCtD
Crizotinib—Loss of consciousness—Dexamethasone—psoriasis	5.39e-05	0.000739	CcSEcCtD
Crizotinib—Dizziness—Mycophenolic acid—psoriasis	5.39e-05	0.000739	CcSEcCtD
Crizotinib—Paraesthesia—Prednisolone—psoriasis	5.39e-05	0.000738	CcSEcCtD
Crizotinib—Malnutrition—Prednisone—psoriasis	5.34e-05	0.000732	CcSEcCtD
Crizotinib—Paraesthesia—Hydrocortisone—psoriasis	5.26e-05	0.000721	CcSEcCtD
Crizotinib—Body temperature increased—Cyclosporine—psoriasis	5.21e-05	0.000714	CcSEcCtD
Crizotinib—Vomiting—Mycophenolic acid—psoriasis	5.18e-05	0.00071	CcSEcCtD
Crizotinib—Dyspepsia—Hydrocortisone—psoriasis	5.16e-05	0.000707	CcSEcCtD
Crizotinib—Rash—Mycophenolic acid—psoriasis	5.14e-05	0.000704	CcSEcCtD
Crizotinib—Dermatitis—Mycophenolic acid—psoriasis	5.13e-05	0.000704	CcSEcCtD
Crizotinib—Decreased appetite—Hydrocortisone—psoriasis	5.09e-05	0.000698	CcSEcCtD
Crizotinib—Body temperature increased—Mycophenolate mofetil—psoriasis	5.08e-05	0.000697	CcSEcCtD
Crizotinib—Urinary tract disorder—Methotrexate—psoriasis	5.06e-05	0.000694	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Hydrocortisone—psoriasis	5.06e-05	0.000693	CcSEcCtD
Crizotinib—Fatigue—Hydrocortisone—psoriasis	5.05e-05	0.000692	CcSEcCtD
Crizotinib—Vision blurred—Prednisone—psoriasis	5.03e-05	0.00069	CcSEcCtD
Crizotinib—Urethral disorder—Methotrexate—psoriasis	5.03e-05	0.000689	CcSEcCtD
Crizotinib—Oedema—Betamethasone—psoriasis	5e-05	0.000686	CcSEcCtD
Crizotinib—Oedema—Dexamethasone—psoriasis	5e-05	0.000686	CcSEcCtD
Crizotinib—Infection—Dexamethasone—psoriasis	4.97e-05	0.000682	CcSEcCtD
Crizotinib—Infection—Betamethasone—psoriasis	4.97e-05	0.000682	CcSEcCtD
Crizotinib—Paraesthesia—Triamcinolone—psoriasis	4.95e-05	0.000679	CcSEcCtD
Crizotinib—Visual impairment—Methotrexate—psoriasis	4.94e-05	0.000677	CcSEcCtD
Crizotinib—Anaemia—Prednisone—psoriasis	4.94e-05	0.000677	CcSEcCtD
Crizotinib—Shock—Betamethasone—psoriasis	4.92e-05	0.000675	CcSEcCtD
Crizotinib—Shock—Dexamethasone—psoriasis	4.92e-05	0.000675	CcSEcCtD
Crizotinib—Dyspnoea—Triamcinolone—psoriasis	4.92e-05	0.000674	CcSEcCtD
Crizotinib—Nervous system disorder—Betamethasone—psoriasis	4.91e-05	0.000673	CcSEcCtD
Crizotinib—Nervous system disorder—Dexamethasone—psoriasis	4.91e-05	0.000673	CcSEcCtD
Crizotinib—Dyspepsia—Triamcinolone—psoriasis	4.85e-05	0.000666	CcSEcCtD
Crizotinib—Nausea—Mycophenolic acid—psoriasis	4.84e-05	0.000663	CcSEcCtD
Crizotinib—Eye disorder—Methotrexate—psoriasis	4.79e-05	0.000657	CcSEcCtD
Crizotinib—Syncope—Prednisone—psoriasis	4.79e-05	0.000656	CcSEcCtD
Crizotinib—Cardiac disorder—Methotrexate—psoriasis	4.76e-05	0.000652	CcSEcCtD
Crizotinib—Fatigue—Triamcinolone—psoriasis	4.75e-05	0.000652	CcSEcCtD
Crizotinib—Asthenia—Cyclosporine—psoriasis	4.73e-05	0.000648	CcSEcCtD
Crizotinib—Loss of consciousness—Prednisone—psoriasis	4.69e-05	0.000643	CcSEcCtD
Crizotinib—Body temperature increased—Hydrocortisone—psoriasis	4.63e-05	0.000635	CcSEcCtD
Crizotinib—Mediastinal disorder—Methotrexate—psoriasis	4.62e-05	0.000633	CcSEcCtD
Crizotinib—Asthenia—Mycophenolate mofetil—psoriasis	4.61e-05	0.000632	CcSEcCtD
Crizotinib—TESK1—Dexamethasone—Clobetasol propionate—psoriasis	4.59e-05	0.0181	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Clobetasol propionate—psoriasis	4.59e-05	0.0181	CbGdCrCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	4.51e-05	0.000619	CcSEcCtD
Crizotinib—Diarrhoea—Cyclosporine—psoriasis	4.51e-05	0.000618	CcSEcCtD
Crizotinib—Paraesthesia—Dexamethasone—psoriasis	4.49e-05	0.000616	CcSEcCtD
Crizotinib—Paraesthesia—Betamethasone—psoriasis	4.49e-05	0.000616	CcSEcCtD
Crizotinib—Malnutrition—Methotrexate—psoriasis	4.46e-05	0.000612	CcSEcCtD
Crizotinib—Dyspepsia—Dexamethasone—psoriasis	4.41e-05	0.000604	CcSEcCtD
Crizotinib—Dyspepsia—Betamethasone—psoriasis	4.41e-05	0.000604	CcSEcCtD
Crizotinib—Diarrhoea—Mycophenolate mofetil—psoriasis	4.4e-05	0.000603	CcSEcCtD
Crizotinib—Dysgeusia—Methotrexate—psoriasis	4.37e-05	0.000599	CcSEcCtD
Crizotinib—Body temperature increased—Triamcinolone—psoriasis	4.36e-05	0.000598	CcSEcCtD
Crizotinib—Dizziness—Cyclosporine—psoriasis	4.36e-05	0.000597	CcSEcCtD
Crizotinib—Oedema—Prednisone—psoriasis	4.36e-05	0.000597	CcSEcCtD
Crizotinib—Decreased appetite—Dexamethasone—psoriasis	4.35e-05	0.000596	CcSEcCtD
Crizotinib—Decreased appetite—Betamethasone—psoriasis	4.35e-05	0.000596	CcSEcCtD
Crizotinib—Infection—Prednisone—psoriasis	4.33e-05	0.000594	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Betamethasone—psoriasis	4.32e-05	0.000592	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Dexamethasone—psoriasis	4.32e-05	0.000592	CcSEcCtD
Crizotinib—Fatigue—Dexamethasone—psoriasis	4.31e-05	0.000591	CcSEcCtD
Crizotinib—Fatigue—Betamethasone—psoriasis	4.31e-05	0.000591	CcSEcCtD
Crizotinib—Shock—Prednisone—psoriasis	4.29e-05	0.000588	CcSEcCtD
Crizotinib—Nervous system disorder—Prednisone—psoriasis	4.27e-05	0.000586	CcSEcCtD
Crizotinib—Dizziness—Mycophenolate mofetil—psoriasis	4.25e-05	0.000583	CcSEcCtD
Crizotinib—Skin disorder—Prednisone—psoriasis	4.23e-05	0.00058	CcSEcCtD
Crizotinib—Vision blurred—Methotrexate—psoriasis	4.21e-05	0.000577	CcSEcCtD
Crizotinib—Asthenia—Hydrocortisone—psoriasis	4.2e-05	0.000576	CcSEcCtD
Crizotinib—Vomiting—Cyclosporine—psoriasis	4.19e-05	0.000574	CcSEcCtD
Crizotinib—Rash—Cyclosporine—psoriasis	4.16e-05	0.00057	CcSEcCtD
Crizotinib—Dermatitis—Cyclosporine—psoriasis	4.15e-05	0.000569	CcSEcCtD
Crizotinib—Anaemia—Methotrexate—psoriasis	4.12e-05	0.000565	CcSEcCtD
Crizotinib—Vomiting—Mycophenolate mofetil—psoriasis	4.09e-05	0.00056	CcSEcCtD
Crizotinib—Rash—Mycophenolate mofetil—psoriasis	4.05e-05	0.000556	CcSEcCtD
Crizotinib—Dermatitis—Mycophenolate mofetil—psoriasis	4.05e-05	0.000555	CcSEcCtD
Crizotinib—Diarrhoea—Hydrocortisone—psoriasis	4.01e-05	0.000549	CcSEcCtD
Crizotinib—Leukopenia—Methotrexate—psoriasis	3.99e-05	0.000548	CcSEcCtD
Crizotinib—Dizziness—Prednisolone—psoriasis	3.97e-05	0.000544	CcSEcCtD
Crizotinib—Asthenia—Triamcinolone—psoriasis	3.96e-05	0.000542	CcSEcCtD
Crizotinib—Body temperature increased—Betamethasone—psoriasis	3.96e-05	0.000542	CcSEcCtD
Crizotinib—Body temperature increased—Dexamethasone—psoriasis	3.96e-05	0.000542	CcSEcCtD
Crizotinib—Nausea—Cyclosporine—psoriasis	3.91e-05	0.000537	CcSEcCtD
Crizotinib—Paraesthesia—Prednisone—psoriasis	3.91e-05	0.000536	CcSEcCtD
Crizotinib—Dizziness—Hydrocortisone—psoriasis	3.87e-05	0.000531	CcSEcCtD
Crizotinib—Dyspepsia—Prednisone—psoriasis	3.84e-05	0.000526	CcSEcCtD
Crizotinib—Nausea—Mycophenolate mofetil—psoriasis	3.82e-05	0.000524	CcSEcCtD
Crizotinib—Decreased appetite—Prednisone—psoriasis	3.79e-05	0.000519	CcSEcCtD
Crizotinib—Rash—Prednisolone—psoriasis	3.78e-05	0.000518	CcSEcCtD
Crizotinib—Dermatitis—Prednisolone—psoriasis	3.78e-05	0.000518	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	3.77e-05	0.000517	CcSEcCtD
Crizotinib—Fatigue—Prednisone—psoriasis	3.76e-05	0.000515	CcSEcCtD
Crizotinib—Constipation—Prednisone—psoriasis	3.73e-05	0.000511	CcSEcCtD
Crizotinib—Vomiting—Hydrocortisone—psoriasis	3.72e-05	0.000511	CcSEcCtD
Crizotinib—Rash—Hydrocortisone—psoriasis	3.69e-05	0.000506	CcSEcCtD
Crizotinib—Dermatitis—Hydrocortisone—psoriasis	3.69e-05	0.000506	CcSEcCtD
Crizotinib—TESK1—Betamethasone—Beclomethasone—psoriasis	3.68e-05	0.0145	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Fluocinonide—psoriasis	3.68e-05	0.0145	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Beclomethasone—psoriasis	3.68e-05	0.0145	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Fluocinonide—psoriasis	3.68e-05	0.0145	CbGdCrCtD
Crizotinib—Dizziness—Triamcinolone—psoriasis	3.65e-05	0.0005	CcSEcCtD
Crizotinib—Infection—Methotrexate—psoriasis	3.62e-05	0.000496	CcSEcCtD
Crizotinib—Asthenia—Betamethasone—psoriasis	3.59e-05	0.000492	CcSEcCtD
Crizotinib—Asthenia—Dexamethasone—psoriasis	3.59e-05	0.000492	CcSEcCtD
Crizotinib—TESK1—Dexamethasone—Fluocinolone Acetonide—psoriasis	3.57e-05	0.0141	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Fluocinolone Acetonide—psoriasis	3.57e-05	0.0141	CbGdCrCtD
Crizotinib—Nervous system disorder—Methotrexate—psoriasis	3.57e-05	0.00049	CcSEcCtD
Crizotinib—Nausea—Prednisolone—psoriasis	3.56e-05	0.000488	CcSEcCtD
Crizotinib—Skin disorder—Methotrexate—psoriasis	3.54e-05	0.000485	CcSEcCtD
Crizotinib—Vomiting—Triamcinolone—psoriasis	3.51e-05	0.000481	CcSEcCtD
Crizotinib—Nausea—Hydrocortisone—psoriasis	3.48e-05	0.000477	CcSEcCtD
Crizotinib—Rash—Triamcinolone—psoriasis	3.48e-05	0.000477	CcSEcCtD
Crizotinib—Dermatitis—Triamcinolone—psoriasis	3.47e-05	0.000476	CcSEcCtD
Crizotinib—Body temperature increased—Prednisone—psoriasis	3.45e-05	0.000472	CcSEcCtD
Crizotinib—Diarrhoea—Dexamethasone—psoriasis	3.42e-05	0.000469	CcSEcCtD
Crizotinib—Diarrhoea—Betamethasone—psoriasis	3.42e-05	0.000469	CcSEcCtD
Crizotinib—Dizziness—Dexamethasone—psoriasis	3.31e-05	0.000454	CcSEcCtD
Crizotinib—Dizziness—Betamethasone—psoriasis	3.31e-05	0.000454	CcSEcCtD
Crizotinib—Nausea—Triamcinolone—psoriasis	3.28e-05	0.000449	CcSEcCtD
Crizotinib—Paraesthesia—Methotrexate—psoriasis	3.27e-05	0.000448	CcSEcCtD
Crizotinib—Dyspnoea—Methotrexate—psoriasis	3.25e-05	0.000445	CcSEcCtD
Crizotinib—Dyspepsia—Methotrexate—psoriasis	3.21e-05	0.00044	CcSEcCtD
Crizotinib—Vomiting—Betamethasone—psoriasis	3.18e-05	0.000436	CcSEcCtD
Crizotinib—Vomiting—Dexamethasone—psoriasis	3.18e-05	0.000436	CcSEcCtD
Crizotinib—Decreased appetite—Methotrexate—psoriasis	3.17e-05	0.000434	CcSEcCtD
Crizotinib—Rash—Betamethasone—psoriasis	3.16e-05	0.000433	CcSEcCtD
Crizotinib—Rash—Dexamethasone—psoriasis	3.16e-05	0.000433	CcSEcCtD
Crizotinib—Dermatitis—Betamethasone—psoriasis	3.15e-05	0.000432	CcSEcCtD
Crizotinib—Dermatitis—Dexamethasone—psoriasis	3.15e-05	0.000432	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Methotrexate—psoriasis	3.14e-05	0.000431	CcSEcCtD
Crizotinib—Fatigue—Methotrexate—psoriasis	3.14e-05	0.00043	CcSEcCtD
Crizotinib—Asthenia—Prednisone—psoriasis	3.13e-05	0.000429	CcSEcCtD
Crizotinib—Diarrhoea—Prednisone—psoriasis	2.98e-05	0.000409	CcSEcCtD
Crizotinib—Nausea—Betamethasone—psoriasis	2.97e-05	0.000407	CcSEcCtD
Crizotinib—Nausea—Dexamethasone—psoriasis	2.97e-05	0.000407	CcSEcCtD
Crizotinib—Dizziness—Prednisone—psoriasis	2.88e-05	0.000395	CcSEcCtD
Crizotinib—Body temperature increased—Methotrexate—psoriasis	2.88e-05	0.000395	CcSEcCtD
Crizotinib—ACVR1—Betamethasone—Hydrocortisone—psoriasis	2.8e-05	0.011	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Hydrocortisone—psoriasis	2.8e-05	0.011	CbGdCrCtD
Crizotinib—Vomiting—Prednisone—psoriasis	2.77e-05	0.00038	CcSEcCtD
Crizotinib—Rash—Prednisone—psoriasis	2.75e-05	0.000377	CcSEcCtD
Crizotinib—Dermatitis—Prednisone—psoriasis	2.75e-05	0.000376	CcSEcCtD
Crizotinib—Asthenia—Methotrexate—psoriasis	2.61e-05	0.000358	CcSEcCtD
Crizotinib—ACVR1—Dexamethasone—Betamethasone—psoriasis	2.6e-05	0.0102	CbGdCrCtD
Crizotinib—ACVR1—Betamethasone—Dexamethasone—psoriasis	2.6e-05	0.0102	CbGdCrCtD
Crizotinib—Nausea—Prednisone—psoriasis	2.59e-05	0.000355	CcSEcCtD
Crizotinib—ACVR1—Dexamethasone—Triamcinolone—psoriasis	2.54e-05	0.01	CbGdCrCtD
Crizotinib—ACVR1—Betamethasone—Triamcinolone—psoriasis	2.54e-05	0.01	CbGdCrCtD
Crizotinib—Diarrhoea—Methotrexate—psoriasis	2.49e-05	0.000342	CcSEcCtD
Crizotinib—ACVR1—Dexamethasone—Prednisone—psoriasis	2.41e-05	0.0095	CbGdCrCtD
Crizotinib—ACVR1—Betamethasone—Prednisone—psoriasis	2.41e-05	0.0095	CbGdCrCtD
Crizotinib—Dizziness—Methotrexate—psoriasis	2.41e-05	0.00033	CcSEcCtD
Crizotinib—ACVR1—Betamethasone—Prednisolone—psoriasis	2.35e-05	0.00927	CbGdCrCtD
Crizotinib—ACVR1—Dexamethasone—Prednisolone—psoriasis	2.35e-05	0.00927	CbGdCrCtD
Crizotinib—Vomiting—Methotrexate—psoriasis	2.32e-05	0.000317	CcSEcCtD
Crizotinib—Rash—Methotrexate—psoriasis	2.3e-05	0.000315	CcSEcCtD
Crizotinib—Dermatitis—Methotrexate—psoriasis	2.29e-05	0.000315	CcSEcCtD
Crizotinib—Nausea—Methotrexate—psoriasis	2.16e-05	0.000297	CcSEcCtD
Crizotinib—TESK1—Betamethasone—Hydrocortisone—psoriasis	1.8e-05	0.00711	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Hydrocortisone—psoriasis	1.8e-05	0.00711	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Betamethasone—psoriasis	1.68e-05	0.0066	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Dexamethasone—psoriasis	1.68e-05	0.0066	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Triamcinolone—psoriasis	1.64e-05	0.00645	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Triamcinolone—psoriasis	1.64e-05	0.00645	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Prednisone—psoriasis	1.55e-05	0.00612	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Prednisone—psoriasis	1.55e-05	0.00612	CbGdCrCtD
Crizotinib—TESK1—Betamethasone—Prednisolone—psoriasis	1.52e-05	0.00597	CbGdCrCtD
Crizotinib—TESK1—Dexamethasone—Prednisolone—psoriasis	1.52e-05	0.00597	CbGdCrCtD
Crizotinib—NTRK1—Signaling Pathways—TYK2—psoriasis	2.02e-06	2.15e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—NOS2—psoriasis	2.02e-06	2.15e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—NFKB1—psoriasis	2.01e-06	2.14e-05	CbGpPWpGaD
Crizotinib—TBK1—Immune System—IL6—psoriasis	2.01e-06	2.14e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—HLA-DRB1—psoriasis	2.01e-06	2.14e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—LEP—psoriasis	2e-06	2.13e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—APOE—psoriasis	2e-06	2.13e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—NFKB1—psoriasis	2e-06	2.13e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—IL6—psoriasis	1.99e-06	2.12e-05	CbGpPWpGaD
Crizotinib—TYK2—Innate Immune System—IL6—psoriasis	1.98e-06	2.11e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—CD4—psoriasis	1.97e-06	2.1e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—JUN—psoriasis	1.97e-06	2.1e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—TP53—psoriasis	1.96e-06	2.09e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TYK2—psoriasis	1.96e-06	2.09e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—TYK2—psoriasis	1.96e-06	2.09e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—TP53—psoriasis	1.95e-06	2.08e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—HLA-A—psoriasis	1.95e-06	2.07e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—JUN—psoriasis	1.95e-06	2.07e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—TP53—psoriasis	1.94e-06	2.07e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—ICAM1—psoriasis	1.93e-06	2.05e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—JUN—psoriasis	1.93e-06	2.05e-05	CbGpPWpGaD
Crizotinib—MAP3K3—Immune System—IL6—psoriasis	1.93e-06	2.05e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NFKBIA—psoriasis	1.92e-06	2.04e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—NFKBIA—psoriasis	1.91e-06	2.04e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—TYK2—psoriasis	1.91e-06	2.04e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—JUN—psoriasis	1.91e-06	2.04e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—VEGFA—psoriasis	1.91e-06	2.03e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—TYK2—psoriasis	1.9e-06	2.03e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—APOE—psoriasis	1.9e-06	2.02e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—NFKB1—psoriasis	1.89e-06	2.02e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—STAT3—psoriasis	1.89e-06	2.01e-05	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—CXCL8—psoriasis	1.88e-06	2e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—NFKB1—psoriasis	1.87e-06	1.99e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—VEGFA—psoriasis	1.87e-06	1.99e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—CXCL8—psoriasis	1.87e-06	1.99e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NFKBIA—psoriasis	1.86e-06	1.98e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CRP—psoriasis	1.86e-06	1.98e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—NFKB1—psoriasis	1.86e-06	1.98e-05	CbGpPWpGaD
Crizotinib—SRC—Axon guidance—IL6—psoriasis	1.85e-06	1.97e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—NFKB1—psoriasis	1.84e-06	1.96e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—CXCL8—psoriasis	1.84e-06	1.96e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.82e-06	1.94e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—TP53—psoriasis	1.82e-06	1.94e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—STAT3—psoriasis	1.82e-06	1.94e-05	CbGpPWpGaD
Crizotinib—JAK3—Immune System—IL6—psoriasis	1.82e-06	1.94e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—IL6—psoriasis	1.82e-06	1.94e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—IL6—psoriasis	1.81e-06	1.93e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—SOCS1—psoriasis	1.8e-06	1.92e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—IL6—psoriasis	1.8e-06	1.91e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—HLA-A—psoriasis	1.8e-06	1.91e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—STAT3—psoriasis	1.8e-06	1.91e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—IFNG—psoriasis	1.79e-06	1.91e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—TYK2—psoriasis	1.79e-06	1.91e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—NFKB1—psoriasis	1.78e-06	1.9e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IFNG—psoriasis	1.78e-06	1.9e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—HLA-DRB1—psoriasis	1.78e-06	1.89e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—TP53—psoriasis	1.78e-06	1.89e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—NOS2—psoriasis	1.77e-06	1.88e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—CXCL8—psoriasis	1.76e-06	1.87e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CARM1—psoriasis	1.74e-06	1.85e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—TP53—psoriasis	1.74e-06	1.85e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—JUN—psoriasis	1.73e-06	1.85e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—CD4—psoriasis	1.73e-06	1.84e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—CD4—psoriasis	1.72e-06	1.83e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—JUN—psoriasis	1.71e-06	1.82e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—ICAM1—psoriasis	1.71e-06	1.82e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CXCL8—psoriasis	1.71e-06	1.82e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—CXCL8—psoriasis	1.71e-06	1.82e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—STAT3—psoriasis	1.7e-06	1.81e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—IL6—psoriasis	1.7e-06	1.81e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—VEGFA—psoriasis	1.7e-06	1.81e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—NFKBIA—psoriasis	1.69e-06	1.8e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—STAT3—psoriasis	1.68e-06	1.79e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TYK2—psoriasis	1.68e-06	1.79e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—APOE—psoriasis	1.68e-06	1.79e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IFNG—psoriasis	1.68e-06	1.78e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—NFKB1—psoriasis	1.67e-06	1.78e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TYK2—psoriasis	1.66e-06	1.77e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—STAT3—psoriasis	1.65e-06	1.76e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—TYK2—psoriasis	1.65e-06	1.76e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—NFKB1—psoriasis	1.65e-06	1.75e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—JUN—psoriasis	1.64e-06	1.74e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—TNF—psoriasis	1.63e-06	1.74e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—IL6—psoriasis	1.63e-06	1.73e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—IL6—psoriasis	1.62e-06	1.73e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—LEP—psoriasis	1.62e-06	1.73e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—APOE—psoriasis	1.62e-06	1.73e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—CD4—psoriasis	1.62e-06	1.72e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—IL6—psoriasis	1.61e-06	1.71e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—IL6—psoriasis	1.6e-06	1.7e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—IL6—psoriasis	1.6e-06	1.7e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—TP53—psoriasis	1.6e-06	1.7e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—SOCS1—psoriasis	1.59e-06	1.7e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—IL6—psoriasis	1.59e-06	1.69e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—JUN—psoriasis	1.59e-06	1.69e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—NFKB1—psoriasis	1.57e-06	1.68e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TYK2—psoriasis	1.57e-06	1.67e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—IL6—psoriasis	1.57e-06	1.67e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—TYK2—psoriasis	1.57e-06	1.67e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—NOS2—psoriasis	1.56e-06	1.67e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—IL6—psoriasis	1.56e-06	1.66e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—IL6—psoriasis	1.55e-06	1.65e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—JUN—psoriasis	1.55e-06	1.65e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—JUN—psoriasis	1.54e-06	1.64e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—NFKB1—psoriasis	1.53e-06	1.63e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—STAT3—psoriasis	1.53e-06	1.63e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—APOE—psoriasis	1.52e-06	1.61e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—LEP—psoriasis	1.52e-06	1.61e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—VEGFA—psoriasis	1.51e-06	1.61e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NFKBIA—psoriasis	1.51e-06	1.61e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—IL6—psoriasis	1.5e-06	1.6e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—STAT3—psoriasis	1.5e-06	1.6e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—CD4—psoriasis	1.49e-06	1.59e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—VEGFA—psoriasis	1.49e-06	1.59e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—NFKB1—psoriasis	1.49e-06	1.59e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—NFKB1—psoriasis	1.48e-06	1.58e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—STAT3—psoriasis	1.48e-06	1.57e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—IFNG—psoriasis	1.47e-06	1.56e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CXCL8—psoriasis	1.46e-06	1.56e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—JUN—psoriasis	1.45e-06	1.54e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—TYK2—psoriasis	1.45e-06	1.54e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CXCL8—psoriasis	1.44e-06	1.54e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—VEGFA—psoriasis	1.43e-06	1.52e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—CAT—psoriasis	1.42e-06	1.51e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—CD4—psoriasis	1.42e-06	1.51e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—STAT3—psoriasis	1.41e-06	1.51e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TP53—psoriasis	1.41e-06	1.51e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NFKBIA—psoriasis	1.41e-06	1.5e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—NFKB1—psoriasis	1.39e-06	1.48e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—TYK2—psoriasis	1.39e-06	1.48e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—VEGFA—psoriasis	1.39e-06	1.48e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—STAT3—psoriasis	1.37e-06	1.46e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CXCL8—psoriasis	1.37e-06	1.46e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—JUN—psoriasis	1.36e-06	1.45e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—JUN—psoriasis	1.34e-06	1.43e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—STAT3—psoriasis	1.34e-06	1.43e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—STAT3—psoriasis	1.33e-06	1.42e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CXCL8—psoriasis	1.33e-06	1.42e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—APOE—psoriasis	1.33e-06	1.41e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—LEP—psoriasis	1.33e-06	1.41e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—IL6—psoriasis	1.32e-06	1.4e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—IL6—psoriasis	1.32e-06	1.4e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—NFKB1—psoriasis	1.31e-06	1.4e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—CD4—psoriasis	1.31e-06	1.39e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—IFNG—psoriasis	1.3e-06	1.38e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—NFKB1—psoriasis	1.29e-06	1.38e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TP53—psoriasis	1.28e-06	1.37e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—TYK2—psoriasis	1.28e-06	1.36e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—JUN—psoriasis	1.27e-06	1.36e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—IL6—psoriasis	1.27e-06	1.35e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—JUN—psoriasis	1.27e-06	1.35e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—IL6—psoriasis	1.26e-06	1.35e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—CD4—psoriasis	1.25e-06	1.34e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—IL6—psoriasis	1.25e-06	1.34e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—STAT3—psoriasis	1.25e-06	1.33e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NFKBIA—psoriasis	1.24e-06	1.32e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TYK2—psoriasis	1.24e-06	1.32e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—JUN—psoriasis	1.24e-06	1.32e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NFKB1—psoriasis	1.23e-06	1.3e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—NFKB1—psoriasis	1.22e-06	1.3e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—IL6—psoriasis	1.19e-06	1.27e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NFKB1—psoriasis	1.19e-06	1.27e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—VEGFA—psoriasis	1.19e-06	1.27e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—STAT3—psoriasis	1.18e-06	1.25e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—IL6—psoriasis	1.18e-06	1.25e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—APOE—psoriasis	1.18e-06	1.25e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—LEP—psoriasis	1.18e-06	1.25e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—VEGFA—psoriasis	1.17e-06	1.25e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—IL6—psoriasis	1.17e-06	1.24e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—STAT3—psoriasis	1.16e-06	1.24e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—CD4—psoriasis	1.16e-06	1.23e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TYK2—psoriasis	1.16e-06	1.23e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—STAT3—psoriasis	1.16e-06	1.23e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—IL6—psoriasis	1.15e-06	1.23e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TP53—psoriasis	1.14e-06	1.22e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—psoriasis	1.13e-06	1.2e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—JUN—psoriasis	1.12e-06	1.2e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—VEGFA—psoriasis	1.11e-06	1.18e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—APOE—psoriasis	1.1e-06	1.17e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—STAT3—psoriasis	1.1e-06	1.17e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—STAT3—psoriasis	1.1e-06	1.17e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NFKBIA—psoriasis	1.1e-06	1.17e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—NFKB1—psoriasis	1.08e-06	1.15e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—psoriasis	1.08e-06	1.15e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—VEGFA—psoriasis	1.08e-06	1.15e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CXCL8—psoriasis	1.08e-06	1.15e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CARM1—psoriasis	1.07e-06	1.14e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—CAT—psoriasis	1.07e-06	1.14e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—STAT3—psoriasis	1.07e-06	1.14e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—IL6—psoriasis	1.07e-06	1.14e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—IL6—psoriasis	1.05e-06	1.12e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—psoriasis	1.05e-06	1.12e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—IL6—psoriasis	1.03e-06	1.1e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TYK2—psoriasis	1.01e-06	1.08e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—STAT3—psoriasis	1.01e-06	1.08e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CXCL8—psoriasis	1.01e-06	1.07e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—JUN—psoriasis	1e-06	1.07e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—IL6—psoriasis	9.88e-07	1.05e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—STAT3—psoriasis	9.71e-07	1.03e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NFKB1—psoriasis	9.63e-07	1.03e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PPARG—psoriasis	9.6e-07	1.02e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—IL6—psoriasis	9.58e-07	1.02e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—IL6—psoriasis	9.58e-07	1.02e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—JUN—psoriasis	9.36e-07	9.97e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—IL6—psoriasis	9.35e-07	9.96e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—IL6—psoriasis	9.31e-07	9.91e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NFKB1—psoriasis	9.01e-07	9.6e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—psoriasis	8.98e-07	9.57e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TYK2—psoriasis	8.97e-07	9.55e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—STAT3—psoriasis	8.97e-07	9.55e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—psoriasis	8.86e-07	9.43e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CXCL8—psoriasis	8.82e-07	9.4e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—IL6—psoriasis	8.75e-07	9.32e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—VEGFA—psoriasis	8.74e-07	9.31e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—STAT3—psoriasis	8.66e-07	9.22e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—psoriasis	8.4e-07	8.95e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—APOE—psoriasis	8.32e-07	8.86e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—IL6—psoriasis	8.22e-07	8.76e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—JUN—psoriasis	8.2e-07	8.74e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—VEGFA—psoriasis	8.18e-07	8.71e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—psoriasis	8.16e-07	8.69e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—IL6—psoriasis	8.11e-07	8.64e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—STAT3—psoriasis	8.1e-07	8.63e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—IL6—psoriasis	8.08e-07	8.61e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NFKB1—psoriasis	7.89e-07	8.41e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CXCL8—psoriasis	7.81e-07	8.32e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—IL6—psoriasis	7.69e-07	8.19e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—IL6—psoriasis	7.66e-07	8.16e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—IL6—psoriasis	7.47e-07	7.95e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—JUN—psoriasis	7.26e-07	7.73e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PPARG—psoriasis	7.24e-07	7.71e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—VEGFA—psoriasis	7.17e-07	7.63e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—STAT3—psoriasis	7.09e-07	7.56e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—IL6—psoriasis	7.08e-07	7.54e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NFKB1—psoriasis	6.99e-07	7.44e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—IL6—psoriasis	6.79e-07	7.23e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—psoriasis	6.61e-07	7.03e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—CAT—psoriasis	6.59e-07	7.02e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—VEGFA—psoriasis	6.34e-07	6.76e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—STAT3—psoriasis	6.28e-07	6.69e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—IL6—psoriasis	6.26e-07	6.67e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—psoriasis	6.18e-07	6.58e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—IL6—psoriasis	6.05e-07	6.44e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—IL6—psoriasis	5.66e-07	6.03e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—psoriasis	5.41e-07	5.77e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—APOE—psoriasis	5.12e-07	5.46e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—IL6—psoriasis	4.96e-07	5.28e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—psoriasis	4.79e-07	5.1e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PPARG—psoriasis	4.46e-07	4.75e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—IL6—psoriasis	4.39e-07	4.67e-06	CbGpPWpGaD
